Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

Journal of Medicinal Chemistry

Volumn 54, Issue 9, 2011, Pages 3206-3221

  Bang Andersen, Benny ^a   Ruhland, Thomas ^a   Jørgensen, Morten ^a   Smith, Garrick ^a   Frederiksen, Kristen ^a   Jensen, Klaus Gjervig ^a   Zhong, Huailing ^b   Nielsen, Søren Møller ^a   Hogg, Sandra ^a   Mørk, Arne ^a   Stensbøl, Tine Bryan ^a  

^a H LUNDBECK A S   (Denmark)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (2 CHLORO 4 METHYLPHENYLSULFANYL)PHENYL]PIPERAZINE; 1 [2 (2,3 DICHLOROPHENYLSULFANYL)PHENYL]PIPERAZINE; 1 [2 (2,3 DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE; 1 [2 (2,4 DICHLOROPHENYLSULFANYL)PHENYL]PIPERAZINE; 1 [2 (2,4 DIMETHYLPHENOXY)PHENYL]PIPERAZINE; 1 [2 (2,4 DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE; 1 [2 (3,4 DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE; 1 [2 (4 CHLOROPHENYLSULFANYL)PHENYL]PIPERAZINE; 1 [2 (4 TOLYL)SULFANYLPHENYL]PIPERAZINE; ANTIDEPRESSANT AGENT; BETA 2 ADRENERGIC RECEPTOR; BUSPIRONE; CITALOPRAM; CYTOCHROME P450; ONDANSETRON; PIPERAZINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN 3A RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; MAJOR DEPRESSION; NONHUMAN; RAT; SEROTONIN BRAIN LEVEL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELL LINE; DEPRESSIVE DISORDER, MAJOR; DRUG PARTIAL AGONISM; DRUG STABILITY; HIPPOCAMPUS; HUMANS; MICROSOMES, LIVER; OOCYTES; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; RECEPTORS, SEROTONIN, 5-HT3; RECOMBINANT PROTEINS; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES; XENOPUS;

EID: 79955856369     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101459g     Document Type: Article

References (60)

1. Kessler, R. C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K. R.; Walters, E. E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication Arch. Gen. Psychiatry 2005, 62, 593-602 (Pubitemid 40973434)
2. Murray, C. J. L.; Lopez, A. D. Evidence-based health policy: lessons from the Global Burden of Disease Study Science 1996, 274, 740-743 (Pubitemid 26398244)
3. Bauer, M.; Monz, B. U.; Montejo, A. L.; Quail, D.; Dantchev, N.; Demyttenaere, K.; Garcia-Cebrian, A.; Grassi, L.; Perahia, D. G. S.; Reed, C.; Tylee, A. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study Eur. Psychiatry 2008, 23, 66-73
4. Rosenzweig-Lipson, S.; Beyer, C. E.; Hughes, Z. A.; Khawaja, X.; Rajarao, S. J.; Malberg, J. E.; Rahman, Z.; Ring, R. H.; Schechter, L. E. Differentiating antidepressants of the future: efficacy and safety Pharmacol. Ther. 2007, 113, 134-153 (Pubitemid 46017069)
5. Papakostas, G. I.; Thase, M. E.; Fava, M.; Nelson, J. C.; Shelton, R. C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents Biol. Psychiatry 2007, 62, 1217-1227 (Pubitemid 350060895)
6. Trivedi, M. H.; Rush, A. J.; Wisniewski, S. R.; Nierenberg, A. A.; Warden, D.; Ritz, L.; Norquist, G.; Howland, R. H.; Lebowitz, B.; McGrath, P. J.; Shores-Wilson, K.; Biggs, M. M.; Balasubramani, G. K.; Fava, M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am. J. Psychiatry 2006, 163, 28-40 (Pubitemid 43050100)
7. Moltzen, E. K.; Bang-Andersen, B. Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century - a medicinal chemistry survey Curr. Top. Med. Chem. 2006, 6, 1801-1823 (Pubitemid 44383201)
8. Mathew, S. J.; Manji, H. K.; Charney, D. S. Novel drugs and therapeutic targets for severe mood disorders Neuropsychopharmacology 2008, 33, 2080-2092 (Pubitemid 351992096)
9. Artigas, F.; Perez, V.; Alvarez, E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors Arch. Gen. Psychiatry 1994, 51, 248-251 (Pubitemid 24081512)
10. Artigas, F.; Adell, A.; Celada, P. Pindolol augmentation of antidepressant response Curr. Drug Targets 2006, 7, 139-147
11. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543 (Pubitemid 41504710)
12. Millan, M. J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 2009, 6, 53-77
13. 2C Antagonist, Inverse Agonist or Partial Agonist. WO 200141701 (A2), 2001.
14. 2C receptors potentiates consequences of serotonin reuptake blockade Neuropsychopharmacology 2004, 29, 1782-1789 (Pubitemid 39336789)
15. Nutt, D. J. Beyond psychoanaleptics - can we improve antidepressant drug nomenclature? J. Psychopharmacol. 2009, 23, 343-345
16. Chang, T.; Fava, M. The future of psychopharmacology of depression J. Clin. Psychiatry 2010, 71, 971-975
17. 1A agonists in the treatment of depression? Biol. Psychiatry 2003, 53, 193-203 (Pubitemid 36135929)
18. 1A receptors induces rapid antidepressant response Neuropsychopharmacology 1997, 16, 333-338 (Pubitemid 27211731)
19. Giovannini, M. G.; Ceccarelli, I.; Molinari, B.; Cecchi, M.; Goldfarb, J.; Blandina, P. Serotonergic modulation of acetylcholine release from cortex of freely moving rats J. Pharmacol. Exp. Ther. 1998, 285, 1219-1225 (Pubitemid 28277921)
20. Matsumoto, M.; Yoshioka, M.; Togashi, H.; Tochihara, M.; Ikeda, T.; Saito, H. Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis J. Pharmacol. Exp. Ther. 1995, 272, 1044-1051
21. Morales, M.; Battenberg, E.; de Lecea, L.; Bloom, F. E. The type 3 serotonin receptor is expressed in a subpopulation of GABAergic neurons in the rat neocortex and hippocampus Brain Res. 1996, 731, 199-202 (Pubitemid 26294923)
22. Yan, Z. Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications Mol. Neurobiol. 2002, 26, 203-216 (Pubitemid 35239800)
23. 3 receptor antagonist and antiemetic properties Eur. J. Pharmacol. 1993, 232, 139-145 (Pubitemid 23080188)
24. Bergeron, R.; Blier, P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors Am. J. Psychiatry 1994, 151, 1084-1086 (Pubitemid 24208651)
25. Gray, D. L.; Xu, W.; Campbell, B. M.; Dounay, A. B.; Barta, N.; Boroski, S.; Denny, L.; Evans, L.; Stratman, N.; Probert, A. Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists Bioorg. Med. Chem. Lett. 2009, 19, 6604-6607
26. Ruhland, T.; Bang, K. S.; Andersen, K. Iron-assisted nucleophilic aromatic substitution on solid phase J. Org. Chem. 2002, 67, 5257-5268 (Pubitemid 34793195)
27. Ruhland, T.; Smith, G. P.; Bang-Andersen, B.; Pueschl, A.; Moltzen, E. K.; Andersen, K. Phenyl-piperazine Derivatives as Serotonin Reuptake Inhibitors. WO 2003029232 (A1), 2003.
28. Louie, J.; Hartwig, J. F. Palladium-catalyzed synthesis of arylamines from aryl halides: mechanistic studies lead to coupling in the absence of tin reagents Tetrahedron Lett. 1995, 36, 3609-3612
29. Guram, A. S.; Rennels, R. A.; Buchwald, S. L. A simple catalytic method for the conversion of aryl bromides to arylamines Angew. Chem., Int. Ed. Engl. 1995, 34, 1348-1350
30. Larsen, S. B.; Bang-Andersen, B.; Johansen, T. N.; Jørgensen, M. Palladium-catalyzed monoamination of dihalogenated benzenes Tetrahedron 2008, 64, 2938-2950
31. Schopfer, U.; Schlapbach, A. A general palladium-catalysed synthesis of aromatic and heteroaromatic thioethers Tetrahedron 2001, 57, 3069-3073 (Pubitemid 32322493)
32. Lenox, R. H.; Frazer, A. Mechanism of Action of Antidepressants and Mood Stabilizers. In Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology; Davis, K. L.; Charney, D.; Coyle, J. T.; Nemeroff, C., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2002; pp 1139 - 1163.
33. 11C]DASB positron emission tomography study Am. J. Psychiatry 2004, 161, 826-835 (Pubitemid 38625335)
34. 3H]MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects Br. J. Pharmacol. 2004, 141, 1015-1023 (Pubitemid 38510085)
35. Owens, M. J.; Krulewicz, S.; Simon, J. S.; Sheehan, D. V.; Thase, M. E.; Carpenter, D. J.; Plott, S. J.; Nemeroff, C. B. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine Neuropsychopharmacology 2008, 33, 3201-3212
36. 3 receptor antagonists in cancer patients Cancer Chemother. Pharmacol. 2004, 54, 185-190 (Pubitemid 39044249)
37. 1A receptors in the primate brain Psychopharmacology 1997, 133, 196-202 (Pubitemid 27404751)
38. 1A receptor Neuropsychopharmacology 2004, 29, 847-859 (Pubitemid 38528764)
39. 1A receptor occupancy in rats Drug Metab. Dispos. 2007, 35, 1387-1392 (Pubitemid 47121780)
40. Moore, N. A.; Bang-Andersen, B.; Brennum, L. T.; Frederiksen, K.; Hogg, S.; Mørk, A.; Sanchez, C.; Smith, D. G.; Stensbøl, T. B.; Zhong, H. Lu AA21004: A Novel Potential Treatment for Mood Disorders. Presented at the 21st European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, August 30-September 3, 2008; Poster P.2.b.015.
41. Moore, N. A.; Bang-Andersen, B.; Brennum, L. T.; Frederiksen, K.; Hogg, S.; Mørk, A.; Sanchez, C.; Smith, D. G.; Stensbøl, T. B.; Zhong, H. Neuropsychopharmacology 2008, 18 (suppl. 4) S321
42. 1A agonist, F13714: a microdialysis study in the rat Br. J. Pharmacol. 2006, 149, 170-178 (Pubitemid 44360098)
43. 1A receptors J. Neurosci. 1998, 18, 10150-10156 (Pubitemid 28543788)
44. Brunello, N.; Blier, P.; Judd, L. L.; Mendlewicz, J.; Nelson, C. J.; Souery, D.; Zohar, J.; Racagni, G. Noradrenaline in mood and anxiety disorders: basic and clinical studies Int. Clin. Psychopharmacol. 2003, 18, 191-202 (Pubitemid 36871870)
45. Laje, R. P.; Berman, J. A.; Glassman, A. H. Depression and nicotine: preclinical and clinical evidence for common mechanisms Curr. Psychiatry Rep. 2001, 3, 470-474
46. Mørk, A.; Brennum, L. T.; Fallon, S.; Bisulco, S.; Frederiksen, K.; Bang-Andersen, B.; Lassen, A. B.; Zhong, H.; Patel, J. G.; Poon, P.; Smith, D. G.; Sanchez, C.; Stensbøl, T. B.; Hogg, S. Pharmacological Profile of Lu AA21004, a Novel Multi-Target Drug for the Treatment of Mood Disorders. Presented at the Society for Neuroscience Meeting, Chicago, IL, October 17-21, 2009; Poster.
47. 1B receptor blockade Psychopharmacology 2003, 167, 153-158 (Pubitemid 36628156)
48. 7 receptor as a mediator and modulator of antidepressant-like behavior Behav. Brain Res. 2010, 209, 99-108
49. 7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents J. Pharmacol. Exp. Ther. 2007, 321, 690-698 (Pubitemid 46624521)
50. Drevets, W. C.; Price, J. L.; Furey, M. L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression Brain Struct. Funct. 2008, 213, 93-118
51. Fanselow, M. S.; Dong, H. W. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010, 65, 7-19
52. Mørk, A.; Kreilgaard, M.; Sanchez, C. The R -enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats Neuropharmacology 2003, 45, 167-173 (Pubitemid 36782529)
53. Beyer, C. E.; Boikess, S.; Luo, B.; Dawson, L. A. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study J. Psychopharmacol. 2002, 16, 297-304 (Pubitemid 35470573)
54. Sanchez, C.; Brennum, L. T.; Storustovu, S.; Kreilgard, M.; Mork, A. Depression and poor sleep: the effect of monoaminergic antidepressants in a pre-clinical model in rats Pharmacol., Biochem. Behav. 2007, 86, 468-476 (Pubitemid 46466878)
55. Blier, P. The pharmacology of putative early-onset antidepressant strategies Eur. Neuropsychopharmacol. 2003, 13, 57-66 (Pubitemid 36313278)
56. Gardier, A. M.; Malagie, I.; Trillat, A. C.; Jacquot, C.; Artigas, F. Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies Fundam. Clin. Pharmacol. 1996, 10, 16-27
57. Wolfe, J. P.; Buchwald, S. L. Scope and limitations of the Pd/BINAP-catalyzed amination of aryl bromides J. Org. Chem. 2000, 65, 1144-1157 (Pubitemid 30117389)
58. Pettit, G. R.; Chamberland, M. R.; Blonda, D. S.; Vickers, M. A. Antineoplastic agents: XI. N -Bis(2-bromoethyl)amines Can. J. Chem. 1964, 42, 1699-1706
59. Kalvass, J. C.; Maurer, T. S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery Biopharm. Drug Dispos. 2002, 23, 327-338 (Pubitemid 36124162)
60. Sánchez, C.; Bergqvist, P. B. F.; Brennum, L. T.; Gupta, S.; Hogg, S.; Larsen, A.; Wiborg, O. Escitalopram, the S -(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities Psychopharmacology 2003, 167, 353-362 (Pubitemid 36754236)